Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Type III secretion system (T3SS) ATPase is a highly conserved enzyme essential for the virulence of numerous pathogenic Gram-negative bacteria, including Salmonella, Pseudomonas, and Shigella [1]. It belongs to the AAA+ family of ATPases and is responsible for providing the metabolic energy required to unfold and translocate effector proteins through the T3SS needle complex into host cells [2]. In the context of flagellar assembly, the homologous ATPase (FliI) powers the export of flagellar components required for bacterial motility [5]. Because these ATPases are critical for the delivery of virulence factors but are not required for basic bacterial survival, they represent promising targets for anti-virulence therapies that disarm pathogens without exerting the strong selective pressure for resistance seen with traditional antibiotics [4]. Current drug discovery efforts focus on small molecules that inhibit the catalytic activity or the essential hexameric oligomerization of the ATPase subunits [1, 2]. Sources: [1] Gao, X. et al. (2018) Front. Microbiol.; [2] Case, H. B. et al. (2020) Antibiotics; [3] UniProt (P0A1B3, O31043); [4] Burgess, E. R. et al. (2016) Expert Opin. Drug Discov.; [5] Minamino, T. & Namba, K. (2008) Nature.
Inhibition of ATP hydrolysis activity, disruption of hexameric oligomerization, and blockade of effector protein translocation through the secretion channel.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Type III secretion system ATPase (SctN) (T3SS ATPase).